A ustralia.
Since the introduction of somatic cell hybridization (Kohler & Milstein, 1975) large scale efforts have been directed towards the production of monoclonal antibodies for the diagnosis and therapy of cancer in man. Monoclonal antibodies have been produced against a number of human tumours, including melanoma (Dippold et al., 1980; Koprowski et al., 1978; Yeh et al., 1979) , lung carcinoma (Kasai et al., 1981; Sikora & Wright, 1981) , mammary carcinoma (Colcher et al., 1981; Schlom et al., 1980 , Thompson et al., 1983 , colorectal carcinoma (Herlyn et al., 1979; Koprowski et al., 1979) as well as other tumours (Deng et al., 1981; Kennett & Gilbert, 1979; Nadler ct al., 1980; Ritz et al., 1980; Sikora & Phillips, 1981; Ueda et al., 1981) . The majority of these antibodies recognise either polymorphic, monomorphic or tissue-specific determinants, whilst others may recognise tumour-specific antigens, although this is questionable. We now describe three different monoclonal antibodies produced to human colon carcinoma which define three subgroups all apparently tumour-specific. One group reacted only with the cell line HT-29, a second with HT-29 and several in vitro lines of neoplastic origin and a third, reactive with colon carcinoma cell lines and fresh tumours obtained from the colon. However, when a range of normal tissues was tested with this latter antibody, it was shown not to be tumour-specific.
Materials and methods
Cell fusion BALB/c mice were immunized with fresh colon carcinoma (2 x 106 cells by the i.p. route) and boosted twice with 107 HT-29 cells (colon carcinoma cell line Fogh & Trempe, 1975) . Fresh tumour cell lines were isolated by teasing and filtering through a sieve, centrifuging and collecting the pellet. The pellet was run on an Isopaque-Ficoll density gradient, viable cells were recovered, washed and the lymphocytes were removed by formation of T cell rosettes (E-RFC) and then centrifuging in another Isopaque-Ficoll gradient. The interface was collected (>95% tumour cells), washed in PBS and the viable tumour cells injected into the mice. Three days later the spleens were removed, fused with the P3-NS-1 -Ag4-1 (NS-1) mouse myeloma (1.6 x 108 spleen cells: 3 x 107 NS-l cells) and distributed into 5 microtitre plates (Costar, Cambridge, Mass., U.S.A.) containing BALB/c thymus cells (7 x 105 cells per well). After several changes of Dulbecco's Modified Eagles Medium (Flow Laboratories, Stanmore, New South Wales, Australia) supplemented with Hypoxanthine-Aminopterin-Thymidine, the tissue culture supernatants were tested for antibody secretion using a rosetting assay (see below). Upon screening, several antibody-producing hybridomas were selected on the basis of their differential reactivity with cell lines (see below). These were cloned by limiting dilution, frozen and stored in liquid nitrogen.
Cell lines All human cell lines were maintained in RPMI 1640 containing 10% heat inactivated newborn calf serum, 4mM glutamine, penicillin (50 IU ml-') and streptomycin (50 IU ml-1) (Glaxo Australia, Boronia, Victoria) as described (Thompson et al., 1983; Jones et al., 1982a (Pihl et al., 1980a) . The fresh tissue samples were cut into 0.5cm blocks and snap frozen in a liquid nitrogen-isopentane slurry and stored at -70°C (Nairn, 1976) . For indirect immunofluorescence (Thompson et al., 1983) The immunoperoxidase technique was performed as described previously (Thompson et al., 1983 (Thompson et al., 1983) .
Blocking with xenogeneic antiserum To determine the relationship of the antigen detected by 250-30.6 and several other antigens, blocking tests were performed. Normal rabbit serum (as a control) and rabbit antisera to carcinoembryonic antigen (CEA) (Pihl et al., 1980a) , to colonic carcinoma mucin (CCM) (Ma et al., 1980) and to a 3 M KCI extract of colonic tumour cells (Jones et al., 1982b) were used to coat HT-29 cells in an attempt to block the binding of the 250-30.6 monoclonal antibody. This was performed by mixing 106 HT-29 cells with 300,u1 of the different rabbit antisera at 1/4 (a dilution representing an excess of antibody) for I h at 4°C. The cells were then washed, centrifuged and the incubation repeated. The coated HT-29 cells were then incubated with the 250-30.6 antibody and the titre determined in a SAMG-RFC assay.
Serum and antigen inhibitions
To detect antigen in serum a rosette inhibition assay was performed wherein serum (25,pl) from patients with colorectal carcinoma, purified CEA (1mgml-1), CCM (lmgml-1) and a 3MKCl extract of HT-29 (1mgml-1) were serially diluted (25 ,l), and then mixed with 25 jul of 250-30.6 (1/200: a dilution which gave 90% rosettes) at 4°C overnight. HT-29 cells were then added and the bound antibody assayed by a SAMG-RFC assay for an inhibition of RFC.
Molecular weight determination Cell surface labelling using 1251 (Phillips & Morrison, 1971 ) and internal labelling using 35S-methionine (Jones et al., 1978) was performed with the HT-29 target cells. After labelling, the cells were lysed in and the lysate reacted with the appropriate antibody. The antigen-antibody complex was precipitated from solution using Staphylococcus aureus Cowan I strain, and after reduction the molecular weight of the antigen was determined from electrophoresed acrylamide (10%) gels (see Thompson et al., 1983 for details).
Results
Details offusion Nine days after cell fusion 480 microtitre wells were screened for the production of antibody by testing the tissue culture supernatants on the HT-29 using the SAMG-RFC assay. Hybrids actively secreting antibody to the HT-29 cells were found in 102/480 wells. Preliminary testing indicated that the majority of these antibodies were also reactive with other human cells, peripheral blood lymphocytes, carcinoma of the lung, carcinoma of the breast, melanoma and the Raji cell line, and these were discarded. Seven antibodies were selected for further study on the basis of their more selective reactivity with colonic carcinoma cell lines; these were cloned twice by limiting dilution and stored frozen. Three different sets of antibodies were subsequently studied: (a) 250-30.6 ; (b) specific; and (c) HT-29 specific plus several other reactions.
The reactivity of 250-30.6 with cell lines After cloning, supernatants were tested on a panel of in vitro produced cell lines. The monoclonal antibody 250-30.6 (IgG2b) bound strongly to and gave a titre of 1:400 by the SAMG-RFC assay. When tested on 6 other colorectal cell lines (Table  I) , all were reactive, but there was no reaction with other human cell lines, including those derived from breast carcinoma (2), melanoma (3), gall bladder and from lymphoid cells. The results obtained by rosetting were all confirmed by membrane immunofluorescence. A cell line derived from carcinoma of the larynx (HEp-2) was weakly positive by immunofluorescence. Thus, antibody 250-30.6, tested by the sensitive rosetting method or by immunofluorescence appeared to be specific for carcinoma of the colon (other than for the weak HEp-2 reaction).
The reactivity of other monoclonal antibodies Six antibodies (250-9, -10, -11, -15, -17) had a low titre (1:32), whereas 250-24, was higher on HT-29 (1:256). These antibodies appeared to be HT-29 specific as they did not react with the other colorectal cell lines (Table I) . However, the antibodies 250-17 and 250-24 also reacted weakly with the breast carcinoma (T47D); and 250-17 had an additional reaction with a kidney carcinoma (Colo 293). Thus 2 groups of antibodies were defined here: (i) those which were HT-29 specific and (ii) those with additional reactivity. Due to its more selective reactivity with colon carcinoma lines subsequent testing was performed only with antibody 250-30.6.
Reaction of 250-30.6 with benign and malignant human tumours by immunofluorescence and immunoperoxidase Immunofluorescent staining patterns produced by monoclonal antibody 250-30.6 on a range of fresh human tumours of different origin were performed (Table II) , and included several metastasising colorectal carcinomas. It was noted that the antibody reacted only with fresh frozen sections and not with formalin fixed paraffin-embedded sections.
In short, the histological studies demonstrated that benign and malignant tumours from the colorectal region were reactive, as were metastases, but other tumours were non-reactive (Figures 1 and  2 ). The antibody also reacted with normal colonic tissue. The details are as follows: (i) In primary colorectal carcinoma the staining was confined to the glandular epithelial cells of the tumour (Figures la, b and 2b) and this was found in 12/12 tumours with varying grades of differentiation (good, intermediate, and poor) . By contrast 4 anaplastic primary colorectal carcinomas were non-reactive, clearly indicating that the expression of the antigen detected by 250-30.6 is related to the stage of differentiation; (ii) When the colorectal tumours had metastasized to different tissues lymph node, liver, lung, and ovary 250-30.6 was also reactive (Figure 1c) , and gave similar staining patterns to that found with the primary tumour; (iii) A number of benign colorectal lesions were also examined villous adenoma, tubulo-villous adenoma and (Tables I and II) . Clearly, as more tissues were examined the antibody appeared to be colonspecific, but later this was amended to specific for the secretory epithelium of certain tissues.
Inhibition with sera from patients with colon carcinoma To determine whether the antibody 250-30.6 could be of value as a diagnostic or monitoring reagent, the serum of ten patients with colorectal carcinoma taken pre-and post-operatively and 10 normal individuals (age-and sex-matched) were tested for their ability to bind to the monoclonal 250-30.6 antibody ( Table IV) . The sera of normal individuals had no inhibitory effect on 250-30.6, but 7/10 postoperative sera inhibited the binding of 250-30.6 to HT-29, indicating that the antigen recognized by 250-30.6 is shed into patients' serum. By contrast only 3/10 pre-operative sera were inhibitory. Typical inhibition data for 3 normal and 2 cancer patients are shown diagrammatically in Figure 3 . An effort to quantitative these serum inhibition results is shown in Table IV "inhibitory units" (I.U.) per ml of serum were calculated on the basis of the antibody dilution which gave a 25% inhibition of the maximum number of rosettes formed, using 25,ul of patients' serum. The inhibition appeared to be unrelated to tumour stage or differentiation, but it was interesting to see that inhibition was absent from the two "A" stage patients, and the majority of inhibition occurred in sera taken post-operatively.
Demonstration that antigen detected by 250-30.6 is distinct from CEA and colon carcinoma mucin To determine if the monoclonal antibody 250-30.6 was recognizing CEA or CCM, blocking experiments with xenogeneic antibodies to these antigens were performed. As shown in Figure 4a the reaction of 250-30.6 was the same whether HT-29 was treated with normal rabbit serum, rabbit anti-CEA or rabbit anti-CCM, indicating that the antigenic determinant recognized by 250-30.6 is distinct from CEA or CCM. Rabbit antiserum to a 3 M KCI extract of partially inhibited the binding of 250-30.6. These studies were pursued further by attempting to inhibit the reaction of the 250-30.6 antibody using purified CEA, CCM or crude HT-29 preparations (Figure 4b ). These components were incubated with 250-30.6 which was then tested on HT-29. It is clear that purified CCM had no inhibitory effect. A partial inhibition occurred with purified CEA, but this was very much less than the inhibition obtained with the HT-29 cell lysate, and is likely to be non-specific. Both an NP-40 cell r ... of antibodies (250-9, 250-10, 250-11, 250-15 and 250-24) (Table I ). The findings raise the possibility that epithelial "subsets" may exist, similar to the lymphocyte subsets defined by the OKT (human) and Ly (mouse) series of monoclonal antibodies.
One monoclonal antibody, 250-30.6, reacted strongly with all 7 colorectal carcinoma cell lines but very weakly with a laryngeal carcinoma (Table  I) (Zamcheck, 1981) obtained from well differentiated tumours, although the serum levels are higher in poorly differentiated tumours (Pihl et al., 1980b) probably reflecting sequestration in the former and extensive spread of the latter. The antigen detected by 250-30.6 did not appear to be CEA or CCM as: (i) purified CEA, and CCM when incubated with the 250-30.6 antibody did not alter antibody binding to (ii) or the more sensitive immunoperoxidase method. In this context the tumour specificity of 250-30.6 disappeared, i.e. the antibody defines an interesting differentiation antigen of epithelial cells, selectively reacting with those of the secretory type.
